Zydus Lifesciences reported a marginal decline in net profit for the fourth quarter ended March 31, 2025. The company posted a consolidated net profit of ₹1,171 crore, down from ₹1,182 crore in the corresponding quarter last year.
Despite the slight dip in profitability, the company saw robust topline growth:
-
Revenue from operations rose 18% YoY to ₹6,528 crore, compared to ₹5,538 crore in Q4 FY24.
-
Total income came in at ₹6,608 crore, up from ₹5,902 crore in the year-ago period.
-
Profit before tax stood at ₹1,672 crore versus ₹1,684 crore in Q4 FY24.
-
Total expenses increased to ₹4,717 crore from ₹4,112 crore in the same quarter last year.
Full-Year FY25 Highlights:
-
Revenue from operations grew to ₹22,574 crore, compared to ₹19,021 crore in FY24.
-
Net profit for the year came in at ₹4,525 crore, up from ₹3,853 crore last year.
-
EBITDA margin remained stable, supported by operational efficiencies and product mix improvements.
While profit was under slight pressure due to increased costs and forex-related impact, the company maintained strong performance in its key segments across domestic and international markets. Zydus continues to invest in new launches and expansion of its specialty portfolio globally.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
